Aeolus Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended March 31, 2017. For the quarter, the company reported contract revenue of $129,000 against $565,000 a year ago. Loss from operations was $1,035,000 against $629,000 a year ago. Net loss was $1,035,000 against $629,000 a year ago. Net loss attributable to common stockholders was $1,035,000 or $0.01 per basic and diluted share against $2,535,000 or $0.02 per basic share a year ago. The increase in net loss was primarily attributable to pre-IND work on AEOL 11114, the company's compound in development for the treatment of Parkinson's disease and lower revenues from the Biomedical Advanced Research and Development Authority. For the six months, the company reported contract revenue of $212,000 against $870,000 a year ago. The revenue is from the BARDA Contract and the decline in revenue is primarily attributable to a lower level of activity under that contract. Loss from operations was $2,122,000 against $1,377,000 a year ago. Net loss was $2,122,000 against $1,662,000 a year ago. Net loss attributable to common stockholders was $2,122,000 or $0.01 per basic and diluted share against $4,148,000 or $0.03 per basic and diluted share a year ago. Net cash used in operating activities was $2,174,000 against $1,755,000 a year ago.